ARQT שווי כולל של נכסי החברה Arcutis

High marketing expenses and the threat of generics create margin risks, intensifying the reliance on a narrow dermatology segment for Arcutis Biotherapeutics (ARQT). Fluctuations in total assets clearly confirm this imbalance, while 420.65 shows the level of this metric. Rising demand for Zoryve and the expansion of insurance limits are correcting the situation, providing the company with long-term growth drivers.

Investors utilize this metric for real-time monitoring of the business's resource base to avoid entering the asset at a valuation peak. The metric is calculated inversely via return on assets (ROA), reflecting the sum of capital and liabilities, while the total asset trend for Arcutis Biotherapeutics (ARQT) confirms business scaling driven by the expansion of Zoryve and broadened insurance coverage.